Drug companies are providing financial support to patient groups that advocate for the approval of their drugs by the National Institute for Health and Care Excellence (Nice), according to an investigation by The Observer. Out of 173 drug appraisals conducted by Nice since April 2021, 138 involved patient groups that had a financial connection to the drug manufacturer being assessed, or had received funding subsequently. The investigation raises concerns about conflicts of interest and efforts by companies to form relationships with groups involved in the appraisal process.
Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.